Table 2.
Trends in the indications for liver biopsy over time
| Total (n=1,944) | Before 2008 (n=456) | 2008 to 2012 (n=859) | After 2013 (n=629) | P-value | |
|---|---|---|---|---|---|
| HBV | 492 (25.3) | 121 (26.5) | 269 (31.3) | 102 (16.2) | <0.001 |
| Malignancy | 398 (20.5) | 158 (34.6) | 135 (15.7) | 105 (16.7) | <0.001 |
| NAFLD | 253 (13.0) | 37 (8.1) | 108 (12.6) | 108 (17.2) | <0.001 |
| Drug-induced liver disease | 228 (11.7) | 25 (5.5) | 109 (12.7) | 94 (14.9) | <0.001 |
| Alcohol-related liver disease | 160 (8.2) | 32 (7.0) | 51 (5.9) | 77 (12.2) | <0.001 |
| Autoimmune hepatitis or PBC | 158 (8.1) | 25 (5.5) | 46 (5.4) | 87 (13.8) | <0.001 |
| HCV | 114 (5.9) | 20 (4.4) | 77 (9.0) | 17 (2.7) | <0.001 |
| Others | 107 (5.5) | 27 (5.9) | 54 (6.3) | 26 (4.1) | <0.001 |
| Etiology of liver cirrhosis | 34 (1.7) | 11 (2.4) | 10 (1.2) | 13 (2.1) | <0.001 |
Values are presented as number (%).
HBV, hepatitis B virus; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; HCV, hepatitis C virus.